Journal Mobile Options
Table of Contents
Vol. 89, No. 2, 2012
Issue release date: September 2012
Section title: Original Paper
Urol Int 2012;89:208–214
(DOI:10.1159/000338910)

Hyperbaric Oxygen Therapy for Radiation Cystitis in Patients with Prostate Cancer: A Long-Term Follow-Up Study

Nakada T.a · Nakada H.f · Yoshida Y.d · Nakashima Y.b · Banya Y.a · Fujihira T.c · Karasawa K.e
Departments of aUrology, bPlastic Surgery and cSurgery, Kuriyama Central Hospital, Yotsukaido, dDepartment of Otolaryngology, Chiba Tokushukai Hospital, Funabashi, eResearch Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, and fDivision of Nursing, Doai Kinen Hospital, Tokyo, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/31/2011 10:08:10 AM
Accepted: 4/7/2012
Published online: 7/10/2012
Issue release date: September 2012

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: http://www.karger.com/UIN

Abstract

Objective: To assess the safety and efficacy of hyperbaric oxygen (HBO) for treating radiation cystitis a long-term follow-up study was done in patients with prostate cancer, the second most common malignancy in Japan. Patients and Methods: A total of 38 patients at an age of 68 ± 8 years with radiation cystitis following irradiation of prostate cancer were treated with HBO at 2 absolute atmospheric pressures for 90 min daily. The average number of HBO treatment sessions in each patient was 62 ± 12. The follow-up period was 11.6 ± 3.7 years. We evaluated objective and subjective symptoms periodically with special reference to the initiation timing of HBO therapy. Results: High efficacy ratios of objective and subjective findings were obtained at 2 and 4 (79–95%) years, respectively. After 7 years’ follow-up, these ratios decreased slightly (72–83%) but still remained stable thereafter (75–88%) without any serious accident. Comparison of late morbidity scores before and 11.6 years after HBO therapy showed significant improvement (p < 0.0005). Twenty-eight patients (74%) obtained nonrecurrent outcome. They had received 18% lower (p < 0.001) radiation dosage than recurrent patients. The interval between the onset of hematuria and start of HBO treatment in nonrecurrent patients was 30% shorter (p < 0.001) than that of recurrent patients. Conclusions: We elucidated the long-term safety and beneficial effect of HBO therapy of radiation cystitis in patients with prostate cancer. Early application of HBO treatment after the onset of hematuria appears to produce favorable outcome.

© 2012 S. Karger AG, Basel


  

Author Contacts

Dr. Teruhiro Nakada
Department of Urology
Kuriyama Central Hospital, 906-1, Kuriyama
Yotsukaido, Chiba 284-0027 (Japan)
Tel. +81 43 421 0007, ext. 893, E-Mail kuri-0203@ifukai.ecweb.jp

  

Article Information

Received: August 31, 2011
Accepted after revision: April 7, 2012
Published online: July 10, 2012
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 4, Number of References : 24

  

Publication Details

Urologia Internationalis

Vol. 89, No. 2, Year 2012 (Cover Date: September 2012)

Journal Editor: Wirth M.P. (Dresden), Porena M. (Perugia), Hakenberg O.W. (Rostock), Castro-Diaz D. (Santa Cruz de Tenerife), Wullich B. (Erlangen)
ISSN: 0042-1138 (Print), eISSN: 1423-0399 (Online)

For additional information: http://www.karger.com/UIN


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/31/2011 10:08:10 AM
Accepted: 4/7/2012
Published online: 7/10/2012
Issue release date: September 2012

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: http://www.karger.com/UIN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.